US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

31.75

+0.36081.15%

Volume:2K

Turnover:77.04K

Market Cap:6.35M

PE:- -

High:31.87

Open:31.87

Low:31.75

Close:31.39

52wk High:43.01

52wk Low:27.40

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.25

T/O Rate:1.21%

Dividend:0.32

Dividend Rate:1.00%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xenon Pharmaceuticals Inc. : Deutsche Bank Cuts to Hold from Buy; Cuts Target Price to $46 from $90

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

Xenon Pharmaceuticals Shares Fall 27,5% Premarket After Co Pauses New Enrollment in Depression Drug Trials

THOMSON REUTERS

Xenon Pharmaceuticals Inc. : RBC Cuts Target Price to $70 from $81

THOMSON REUTERS

Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments

Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects

Xenon Submits FDA NDA for Azetukalner in Focal Seizures

Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies

THOMSON REUTERS

Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

THOMSON REUTERS

Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027

THOMSON REUTERS

Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)

多所顶尖高校获国家批准新增博士学位授权点

KPMG Forecasts China's Smart Wearables Market to Hit RMB 105.3 Billion by 2025, With an 11% Annual Growth Rate

Alkermes Appoints Anne Whitaker to Board of Directors

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

THOMSON REUTERS

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)

Scholar Rock says FDA requested pregnancy safety study for Isembyld

Scholar Rock Shares Fall After Barclays Downgrade

MT Newswires Live

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IBRN/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":31.7536,"timestamp":1791576000000,"preClose":31.3928,"halted":0,"volume":2418,"delay":0,"changeRate":0.011493081216074945,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Post-Mkt","change":0.3608,"latestTime":"10-09 19:24:36 EDT","open":31.865,"high":31.865,"low":31.7536,"amount":77040,"amplitude":0.003549,"askPrice":47.76,"askSize":100,"bidPrice":30.03,"bidSize":4,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791590400000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":31.3928,"sharesOutstanding":150000,"nav":31.865918,"aum":6373183.6,"dividendRate":0.010034,"bidAskSpread":0,"volumeRatio":1.254019,"impliedVol":0.1612,"impliedVolPercentile":0.8327},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.254019,"shares":200000,"dividePrice":0.3186,"high":31.865,"amplitude":0.003549,"preClose":31.3928,"low":31.7536,"week52Low":27.4025,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":31.7536,"committee":-0.923077,"eps":0,"divideRate":0.010034,"volume":2418,"delay":0,"ttmEps":0,"open":31.865,"prevYearClose":32.3193,"prevWeekClose":32.552,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":32.552,"twentyDayClose":37.4262,"sixtyDayClose":38.0334},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668205940","title":"Xenon Pharmaceuticals Inc. : Deutsche Bank Cuts to Hold from Buy; Cuts Target Price to $46 from $90","url":"https://stock-news.laohu8.com/highlight/detail?id=2668205940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668205940?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:08","pubTimestamp":1789729727,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940452","title":"Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940452?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:50","pubTimestamp":1789728612,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB) w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neuronetics-stim-xenon-xene-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neuronetics-stim-xenon-xene-and-biogen-biib-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SBIO","BIIB","XENE","XBI","XLV","IBRN","BK4588","BK4137","STIM","BK4532","BK4082","PBE","HCSG","LU0029874061.USD","BMED","IE00B19Z9Z06.USD","LU0889565916.HKD","LU0128526141.USD","BK4533","LABU","LU0234570918.USD","LU0109394709.USD","BK4581","LU0320765992.SGD","BK4139","IE00B19Z9P08.USD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668619946","title":"Xenon Pharmaceuticals Shares Fall 27,5% Premarket After Co Pauses New Enrollment in Depression Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2668619946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668619946?lang=en_us&edition=fundamental","pubTime":"2026-09-18 16:05","pubTimestamp":1789718717,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nL4N45A0OY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","BK4139","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668124829","title":"Xenon Pharmaceuticals Inc. : RBC Cuts Target Price to $70 from $81","url":"https://stock-news.laohu8.com/highlight/detail?id=2668124829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668124829?lang=en_us&edition=fundamental","pubTime":"2026-09-18 12:30","pubTimestamp":1789705824,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN4590QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","IBRN","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668990047","title":"Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments","url":"https://stock-news.laohu8.com/highlight/detail?id=2668990047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668990047?lang=en_us&edition=fundamental","pubTime":"2026-09-18 07:08","pubTimestamp":1789686480,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals said adverse events in trials of azetukalner to treat depression and bipolar disorder led it to pause enrollment voluntarily. Shares tumbled 26%, to $42.35, after Thursday's bell.Ultragenyx Pharmaceutical's Fayuvi drug received Food and Drug Administration approval to treat children with Sanfilippo syndrome type A. The stock closed up 13%, at $14.50, and gained another 1.7% after the bell.BRT Apartments said its board approved a $10 million replenishment for its stock-buyback program. Shares rose 2.9%, to $14.22, after-hours.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4139","BRT","XENE","IBRN","BK4215","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668501992","title":"Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2668501992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668501992?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:27","pubTimestamp":1789676867,"startTime":"0","endTime":"0","summary":"BUZZ-Xenon Pharma plunges after pausing trial enrollment due to side effects** Shares of Xenon PharmaceuticalsXENE.Oslides 21.59% to $44.97 in extended trading** Xenon says it pauses enrollment of new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4N4591PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668947909","title":"Xenon Submits FDA NDA for Azetukalner in Focal Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2668947909","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668947909?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675304,"startTime":"0","endTime":"0","summary":"Xenon submits FDA NDA for azetukalner in focal seizuresXenon submitted an FDA New Drug Application for azetukalner to treat focal seizures.Filing supported by positive Phase 2b X-TOLE and Phase 3 X-TO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL6fvsBp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4588","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","XENE","IE00BN0W2W23.USD","IE00BQXX3F31.USD","LU2095319765.USD","LU2210149790.SGD","IE00BQXX3C00.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4139","BCDF","BK4585","SG9999014005.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","BK4112","IE00BN0W2V16.EUR","IBRN","IE00BQXX3D17.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994767","title":"Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994767?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","SBIO","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994765","title":"Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994765?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994750","title":"Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994750?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE","IBRN","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994710","title":"Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994710?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","BK4139","IBRN","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996274","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996274?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS), Twist Bioscience (TWST) and Medpa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","IDNA","MEDP","LU2065170008.USD","PSCH","IBRN","LU0029874061.USD","BK4585","XBI","PSIL","BK4581","LU2065171311.SGD","ALKS","MEDX","BK4137","XLV","WDNA","BK4121","LABU","LU2065171402.SGD","LU0128526141.USD","BK4588","GNOM","TWST","ARKG","LU2065169927.USD","HCSG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180672075","title":"多所顶尖高校获国家批准新增博士学位授权点","url":"https://stock-news.laohu8.com/highlight/detail?id=1180672075","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180672075?lang=en_us&edition=fundamental","pubTime":"2026-09-17 18:40","pubTimestamp":1789641650,"startTime":"0","endTime":"0","summary":"国务院学位委员会近期正式公布了2025年度及2026年度学位授予资格自主审核单位的学位点撤销与增设名单。截至目前，包括中国人民大学、天津大学、东北大学、大连理工大学和中南大学在内的多所知名高校，均已宣布成功获批增设博士点。根据中国人民大学心理学系发布的消息，国务院学位委员会近日公布了2026年度自主审核单位增设学位点名单。中国人民大学正式设立了心理学一级学科博士点（代码0402），这标志着该校心理...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166786604","title":"KPMG Forecasts China's Smart Wearables Market to Hit RMB 105.3 Billion by 2025, With an 11% Annual Growth Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=1166786604","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166786604?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:14","pubTimestamp":1789560867,"startTime":"0","endTime":"0","summary":"KPMG's latest industry report reveals that China's smart wearables sector continues its rapid expansion, with market value climbing from RMB 69.5 billion in 2021 to RMB 105.3 billion in 2025. This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","AIPO","QTOC","MNTL","CHAT","VTHR","BCI","IBRN","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607455","title":"Alkermes Appoints Anne Whitaker to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607455","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607455?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556448,"startTime":"0","endTime":"0","summary":"Alkermes appoints Anne Whitaker to board of directorsAlkermes appointed Anne C. Whitaker as an independent director to its board.Whitaker is a biopharmaceutical executive with commercial, operational,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL86gXCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4139","PSIL","PSCH","MEDX","ALKS","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607123","title":"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607123?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA78XSXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4139","PSCH","FBT","IBRN","MEDX","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667078256","title":"Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667078256","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667078256?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:30","pubTimestamp":1789554624,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-alnylam-pharma-alny-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-alnylam-pharma-alny-scholar-rock-holding-srrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","HCSG","LU0320765992.SGD","IBRN","LU0114720955.EUR","SRRK","THNR","GNMX","LABU","ALNY","XBI","BK4581","XLV","LU0882574055.USD","BK4585","BK4139","BK4588","LU0889565916.HKD","LU0109394709.USD","LU0128526141.USD","BK4137","LU0029874061.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667624691","title":"Scholar Rock says FDA requested pregnancy safety study for Isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2667624691","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667624691?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:55","pubTimestamp":1789502119,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) disclosed earlier today on a live audio webcast yesterday announcing the Food and Drug Administration has approved Isembyld, th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-says-fda-requested-pregnancy-safety-study-for-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-says-fda-requested-pregnancy-safety-study-for-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["THNR","BK4585","LABU","BK4588","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667621196","title":"Scholar Rock Shares Fall After Barclays Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2667621196","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667621196?lang=en_us&edition=fundamental","pubTime":"2026-09-16 02:59","pubTimestamp":1789498767,"startTime":"0","endTime":"0","summary":"Scholar Rock  shares were down about 5.2% in Tuesday trading after Barclays downgraded the stock to equalweight from overweight and raised its price target to $58 from $55.Intraday trading volume stood at nearly 3.5 million shares against a daily average of roughly 1.4 million.Price: 49.16, Change: -2.69, Percent Change: -5.19","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667962190","title":"Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667962190","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667962190?lang=en_us&edition=fundamental","pubTime":"2026-09-16 02:52","pubTimestamp":1789498323,"startTime":"0","endTime":"0","summary":"Scholar Rock  could face some friction during the early commercialization of Isembyld after the drugmaker clarified that the US Food and Drug Administration has required a post-marketing pregnancy safety study and requested 15-day reports for serious and non-serious fracture cases, Truist Securities said in a note Tuesday.The FDA recently approved Isembyld to treat spinal muscular atrophy in adults and children two years of age and older.The fracture rate observed in the Isembyld trial appears consistent with historical rates in patients with spinal muscular atrophy, while management reported no change in bone mineral density in the Phase 2 EMBRACE study, Truist said.The brokerage expects fracture reports to be reflected in periodic FDA Adverse Event Reporting System updates, as Scholar Rock does not expect to announce individual new fracture cases.Truist continues to see potential for Isembyld to reach peak sales of $2.3 billion.Truist maintained a buy rating with $76 price target.Pri","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IBRN","BK4585","SRRK","BK4588","LABU","THNR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}